P. Bigini, M. Gobbi, M. Bnati, A. Clavenna, M. Zucchetti, S. Garattini, and G. Pasut
November 4, 2021
Nature Nanotechnology
Istituto di Ricerche Farmacologiche Mario Negri (Italy)

Commentary article

document
adverse events,COVID-19,lipid nanoparticles,mRNA,vaccine ingredients,vaccines